Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is a clinical-stage biotechnology company pioneering targeted therapies for cancers with high unmet medical needs. This page serves as the definitive source for verified news and official updates, providing stakeholders with timely insights into the company's progress in oncology drug development.
Investors and researchers will find curated press releases covering clinical trial milestones, regulatory developments, and strategic partnerships. Key focus areas include updates on Salarius' protein degradation therapies and inhibitor candidates, financial disclosures, and collaborative research initiatives in precision medicine.
All content is rigorously sourced from SEC filings, corporate communications, and validated industry reports. The repository is maintained to support informed analysis while adhering to financial compliance standards. Bookmark this page for efficient tracking of SLRX's advancements in addressing gene dysregulation through innovative biopharmaceutical approaches.
Salarius Pharmaceuticals (NASDAQ: SLRX) recently provided an update on its developmental progress and future plans. The company’s lead candidate, seclidemstat, is advancing in a Phase 1/2 clinical trial for Ewing and related sarcomas, with interim data expected by year-end. Noteworthy is the expansion to 17 clinical sites, including prestigious institutions. Furthermore, the newly acquired SP-3164 is being developed as a targeted protein degrader. Salarius maintains strong financials with $22.6 million in cash, ensuring well-funded operations into 2023.
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) has announced the expansion of its Phase 1/2 clinical trial for seclidemstat, a novel treatment for Ewing’s sarcoma and FET-rearranged sarcomas, to include two Mayo Clinic locations in Minnesota and Florida. This trial aims to explore seclidemstat's efficacy and safety in treating pediatric bone cancer and other related sarcomas. Interim data is expected in the second half of 2022, with hopes that seclidemstat will positively impact patient outcomes.
Salarius Pharmaceuticals (NASDAQ: SLRX) has expanded its ongoing Phase 1/2 clinical trial of seclidemstat for Ewing’s sarcoma and related sarcomas to 15 U.S. trial sites, including the prestigious Seattle Cancer Care Alliance and Oregon Health & Sciences University. The trial explores seclidemstat, a targeted LSD1 inhibitor, in various combinations and as a single agent. Interim data is expected in the second half of 2022. Salarius aims to improve prospects for patients with limited treatment options, with seclidemstat already receiving FDA designations for its potential.
Salarius Pharmaceuticals (NASDAQ: SLRX) has announced a collaboration with VolitionRx Limited to enhance the development of its cancer treatment, seclidemstat, utilizing Volition's Nu.Q® technology for rapid epigenetic profiling. Seclidemstat is currently in Phase 1/2 clinical trials targeting various cancers. This partnership aims to derive valuable biomarker data to assess drug activity and engagement noninvasively. Salarius is advancing its programs, including support from the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas.
Salarius Pharmaceuticals (Nasdaq: SLRX) will release its Q2 2022 financial results on August 5, 2022, followed by a conference call on August 8, 2022, at 11:00 a.m. ET. The call will discuss financial results for the quarter ending June 30, 2022, alongside recent business updates and upcoming milestones. Salarius is focused on developing cancer therapies like seclidemstat for pediatric cancers and sarcomas. The company has received key designations from the FDA and has ongoing clinical trials, bolstered by support from the National Pediatric Cancer Foundation and CPRIT.
Salarius Pharmaceuticals (NASDAQ:SLRX) announced its participation in the 2022 BIO International Convention in San Diego from June 13-16. The company will update on two drug candidates: SP-3164, a next-generation protein degrader targeting cancer-causing proteins, and seclidemstat, its lead candidate in a Phase 1/2 trial for relapsed Ewing sarcoma. Expected clinical readouts for seclidemstat will occur in the latter half of 2022. CEO David Arthur emphasized the potential of their pipeline to address underserved cancers, reinforcing the importance of the convention for business development opportunities.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation, available on-demand starting May 24, will highlight the company's recent achievements and upcoming milestones related to its leading products, seclidemstat and SP-3164. The presentation can be accessed via a dedicated link and will be available for replay for 90 days. Salarius is focused on developing therapies for sarcomas and pediatric cancers, with seclidemstat currently in clinical trials for Ewing sarcoma.
Salarius Pharmaceuticals (SLRX) reports significant advancements in its drug development programs, notably with SP-3164 and seclidemstat. The FDA pre-IND meeting for SP-3164 has been successfully completed, setting the stage for further studies. Financially, Salarius had $24.2 million in cash as of March 31, 2022, but reported a net loss of $6.1 million for Q1 2022, up from $1.9 million in Q1 2021, primarily due to increased R&D expenses. The annual stockholders meeting is scheduled for June 15, 2022, inviting participation in key proposals.
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced plans to submit an Investigational New Drug (IND) application for SP-3164 in 2023 after successfully completing a pre-IND meeting with the FDA. SP-3164 is a next-generation targeted protein degrader aimed at treating hematological and solid tumors. This novel agent may effectively eliminate cancer-causing proteins. The FDA provided critical feedback aiding in the preparation for the IND submission and subsequent clinical trials. Salarius aims to leverage SP-3164 amidst its ongoing clinical programs in an evolving cancer treatment landscape.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced a conference call scheduled for May 12, 2022, at 5:00 p.m. ET to discuss its financial results for the first quarter of 2022. Interested participants can join via phone or listen to the live webcast on the company's investor relations website. Salarius is focused on developing innovative cancer therapies, including seclidemstat, which is in clinical trials for conditions such as Ewing sarcoma. The product has received multiple designations from the FDA, emphasizing its potential in treating unmet medical needs.
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
